Identifying biomarkers for predicting kidney injury after heart surgery
Predicting Poor Outcomes of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers
This study is trying to find new ways to spot kidney injury early in patients after heart surgery to help improve their care and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5010 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Shanghai Zhongshan Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT04962412 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify and validate novel biomarkers and functional tests for detecting acute kidney injury (AKI) associated with cardiac surgery. By focusing on a large cohort of patients undergoing cardiac surgery, the study seeks to improve early detection of AKI, understand its progression, and predict poor outcomes. The research addresses the limitations of current biomarkers, which may be expensive or not reimbursed in various countries. The findings could lead to better management strategies for patients at risk of AKI following cardiac procedures.
Who should consider this trial
Good fit: Ideal candidates for this study are patients scheduled to undergo cardiac surgery.
Not a fit: Patients with end-stage renal disease, those on dialysis, or with a do-not-resuscitate order will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and management of acute kidney injury in patients undergoing cardiac surgery, potentially reducing morbidity and mortality.
How similar studies have performed: Other studies have explored biomarkers for AKI, but this approach focuses specifically on cardiac surgery-associated AKI, making it a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing cardiac surgery were prospectively enrolled. Exclusion Criteria: * History of End Stage Renal Disease or on Dialysis; * prior kidney transplantation; * patients with a DNR order; * patients without written informed consent; * pregnancy; * moribund patients with expected death within 24 h or whose survival to 28 days was unlikely due to an uncontrollable comorbidity (i.e., end-stage liver or heart disease, untreatable malignancy)
Where this trial is running
Shanghai
- Zhongshan hospital, Fudan university — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Guo-wei Tu, MD
- Email: tu.guowei@zs-hospital.sh.cn
- Phone: 86-021-64041990
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.